Edition:
United States

Profile: Shire PLC (SHP.L)

SHP.L on London Stock Exchange

5,120.00GBp
12:11pm EDT
Change (% chg)

-88.00p (-1.69%)
Prev Close
5,208.00p
Open
5,185.00p
Day's High
5,197.00p
Day's Low
5,105.00p
Volume
1,885,168
Avg. Vol
2,784,437
52-wk High
5,377.00p
52-wk Low
2,707.19p

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Company Address

Shire PLC

Hampshire Intl Business Park, Ch
BASINGSTOKE     RG24 8EP
P: +441256.894000
F: +441256.894708

Company Web Links